These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28951258)

  • 1. Ibrutinib suppresses alloantibody responses in a mouse model of allosensitization.
    Kim I; Wu G; Chai NN; Klein AS; Jordan S
    Transpl Immunol; 2017 Dec; 45():59-64. PubMed ID: 28951258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological characterization of de novo and recall alloantibody suppression by CTLA4Ig in a mouse model of allosensitization.
    Kim I; Wu G; Chai NN; Klein AS; Jordan SC
    Transpl Immunol; 2016 Sep; 38():84-92. PubMed ID: 27507323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-interleukin 6 receptor antibodies attenuate antibody recall responses in a mouse model of allosensitization.
    Kim I; Wu G; Chai NN; Klein AS; Jordan S
    Transplantation; 2014 Dec; 98(12):1262-70. PubMed ID: 25286051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD3ε induces splenic B220lo B-cell expansion following anti-CD20 treatment in a mouse model of allosensitization.
    Todo T; Wu G; Chai NN; He Y; Martins G; Gupta A; Fair J; Liu NY; Jordan S; Klein A
    Int Immunol; 2012 Aug; 24(8):529-38. PubMed ID: 22531063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib treatment improves T cell number and function in CLL patients.
    Long M; Beckwith K; Do P; Mundy BL; Gordon A; Lehman AM; Maddocks KJ; Cheney C; Jones JA; Flynn JM; Andritsos LA; Awan F; Fraietta JA; June CH; Maus MV; Woyach JA; Caligiuri MA; Johnson AJ; Muthusamy N; Byrd JC
    J Clin Invest; 2017 Aug; 127(8):3052-3064. PubMed ID: 28714866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD20 antibody suppresses anti-HLA antibody formation in a HLA-A2 transgenic mouse model of sensitization.
    Wu GD; He Y; Chai NN; Toyoda M; Dunn R; Kehry MR; Klein AS; Jordan SC
    Transpl Immunol; 2008 Jul; 19(3-4):178-86. PubMed ID: 18595710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice.
    Nam HY; Nam JH; Yoon G; Lee JY; Nam Y; Kang HJ; Cho HJ; Kim J; Hoe HS
    J Neuroinflammation; 2018 Sep; 15(1):271. PubMed ID: 30231870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B lymphocytes inactivation by Ibrutinib limits endometriosis progression in mice.
    Riccio LGC; Jeljeli M; Santulli P; Chouzenoux S; Doridot L; Nicco C; Reis FM; Abrão MS; Chapron C; Batteux F
    Hum Reprod; 2019 Jul; 34(7):1225-1234. PubMed ID: 31247078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Use of Tocilizumab and Mesenchymal Stem Cells Attenuate the Development of an Anti-HLA-A2.1 Antibody in a Highly Sensitized Mouse Model.
    Fang X; Cui S; Lee H; Min JW; Lim SW; Oh EJ; Yang CW; Shin YJ; Chung BH
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BAFF Inhibition Effectively Suppresses the Development of Anti-HLA.A2 Antibody in the Highly Sensitized Mouse Model.
    Min JW; Shin YJ; Lee H; Kim BM; Park KH; Doh KC; Kim TM; Lim SW; Yang CW; Oh EJ; Chung BH
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APRIL/BLyS Blockade Reduces Donor-specific Antibodies in Allosensitized Mice.
    Wilson NA; Bath NM; Verhoven BM; Ding X; Boldt BA; Sukhwal A; Zhong W; Panzer SE; Redfield RR
    Transplantation; 2019 Jul; 103(7):1372-1384. PubMed ID: 30830041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
    Gayko U; Fung M; Clow F; Sun S; Faust E; Price S; James D; Doyle M; Bari S; Zhuang SH
    Ann N Y Acad Sci; 2015 Nov; 1358():82-94. PubMed ID: 26348626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.
    Stiff A; Trikha P; Wesolowski R; Kendra K; Hsu V; Uppati S; McMichael E; Duggan M; Campbell A; Keller K; Landi I; Zhong Y; Dubovsky J; Howard JH; Yu L; Harrington B; Old M; Reiff S; Mace T; Tridandapani S; Muthusamy N; Caligiuri MA; Byrd JC; Carson WE
    Cancer Res; 2016 Apr; 76(8):2125-36. PubMed ID: 26880800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
    Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal anti-interleukin-6 receptor antibody attenuates donor-specific antibody responses in a mouse model of allosensitization.
    Wu G; Chai N; Kim I; Klein AS; Jordan SC
    Transpl Immunol; 2013 Mar; 28(2-3):138-43. PubMed ID: 23562586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase.
    Mina-Osorio P; LaStant J; Keirstead N; Whittard T; Ayala J; Stefanova S; Garrido R; Dimaano N; Hilton H; Giron M; Lau KY; Hang J; Postelnek J; Kim Y; Min S; Patel A; Woods J; Ramanujam M; DeMartino J; Narula S; Xu D
    Arthritis Rheum; 2013 Sep; 65(9):2380-91. PubMed ID: 23754328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes.
    Wei L; Su YK; Lin CM; Chao TY; Huang SP; Huynh TT; Jan HJ; Whang-Peng J; Chiou JF; Wu AT; Hsiao M
    Oncotarget; 2016 Oct; 7(43):69961-69975. PubMed ID: 27564106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.
    Dubovsky JA; Flynn R; Du J; Harrington BK; Zhong Y; Kaffenberger B; Yang C; Towns WH; Lehman A; Johnson AJ; Muthusamy N; Devine SM; Jaglowski S; Serody JS; Murphy WJ; Munn DH; Luznik L; Hill GR; Wong HK; MacDonald KK; Maillard I; Koreth J; Elias L; Cutler C; Soiffer RJ; Antin JH; Ritz J; Panoskaltsis-Mortari A; Byrd JC; Blazar BR
    J Clin Invest; 2014 Nov; 124(11):4867-76. PubMed ID: 25271622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.
    Bhatt V; Alejandro L; Michael A; Ganetsky A
    Pharmacotherapy; 2014 Mar; 34(3):303-14. PubMed ID: 24338680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.